PROFESSIONAL EDITION

The largest community of pharma leaders

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced…

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)—- $MRK #MRK–KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement in OS, PFS and ORR vs Chemotherapy in Advanced Endometrial Cancer

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles